Kaitlin J. Basham

Aug 23, 2024 | digitalcommons.library.tmc.edu | Javier Leo |Eleonora Dondossola |Kaitlin J. Basham |Nathaniel Wilson

The androgen receptor (AR) is one of the oldest therapeutic targets in oncology and continues to dominate the treatment landscape for advanced prostate cancer, where nearly all treatment regimens include some form of AR modulation. In this regard, AR remains the central driver of prostate cancer cell biology. Emerging preclinical and clinical data implicate key roles for AR in additional cancer types, thereby expanding the importance of this drug target beyond prostate cancer.